Skip to main content

Table 1 Demographic and clinical features of the SSc patients

From: Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study

Variable Patients with SSc (n 70)
Gender (F/M), (%) 65/5 (92.9/7.1)
RP duration (years), mean ± SD 5.10 ± 6.15
Disease duration (years), mean ± SD 9.41 ± 6.26
Cutaneous subset (Diffuse/Limited), n (%) 25/45 (35.7/64.3)
Modified Rodnan cutaneous score 13.11 ± 10.55
Calcinosis, n (%) 11 (15.7)
Telangiectasias, n (%) 38 (54.3)
Active digital ulcers, n (%) 14 (20.0)
Arthritis, n (%) 20 (28.6)
Esophageal involvement, n (%) 53 (75.7)
FVC < 70% predicted, n (%) 19 (27.1)
Interstitial lung involvement on CT scan, n (%) 34 (48.6)
PAH, n (%) 7 (10.0)
Renal crisis, n (%) 3 (4.3)
C-reactive protein (mg/L) 8.81 ± 8.97
ACA, n (%) 28 (40.0)
Anti-Scl-70, n (%) 21 (30.0)
Anti-RNA polymerase III, n (%) 5 (7.1)
IgG anti-cardiolipin 2 (2.9)
IgM anti-cardiolipin 3 (4.3)
IgG anti-beta 2 glycoprotein 1 0 (0.0)
IgM anti-beta 2 glycoprotein 1 1 (1.4)
Lupus anticoagulant 0 (0.0)
  1. Results are presented as mean ± standard deviation or absolute frequency (relative frequency)
  2. RP Raynaud’s phenomenon, FVC forced vital capacity, CT computed tomography, PAH pulmonary arterial hypertension